drugset
drugset / Trial / NCT04755894

HDDO-1756 Bio Equivalence Study

NCT04755894 ↗

Phase 1 Completed 56 enrolled Hyundai Pharmaceutical Co., LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.

Timeline

Start
2020-06-12
Primary completion
2020-06-19
Completion
2020-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject HDDO-1756 Unknown — —
Comparator HDDO-17561 Unknown — —
Comparator HDDO-17562 Unknown — —

Indications

hyperlipidemia